GLPwatch
2026-03-03
- FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s The FDA issued 30 warning letters to telehealth companies for falsely or misleadingly marketing compounded GLP-1 drugs, claiming they are equivalent to FDA-approved products. The agency emphasized that compounded drugs are not FDA-reviewed for safety or effectiveness and are not the same as generics, while continuing its broader crackdown on deceptive pharmaceutical advertising. Read more →